STAND UP TO CANCER ANNOUNCES $1 MILLION DONATION FROM ZENTALIS PHARMACEUTICALS TO FUND TARGETED CANCER THERAPY RESEARCH

Funds Will Support the SU2C Catalyst program and the Study of Small Molecule Inhibitors for Treating Cancer LOS ANGELES, March 15, 2022 /PRNewswire/ -- Stand Up To CancerĀ® (SU2C) and Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced that Zentalis will contribute $1 million to...

Click to view original post